Kamada Ltd.
KMDANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for KMDA. That does not mean none is planned.
Get an email about KMDA's next catalysts
Track Kamada (KMDA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
How KMDA's past catalysts played out
Market Overview
Stock performance and key metrics
Kamada Ltd. is a global biopharmaceutical company specializing in the research, manufacturing, and commercialization of specialty pharmaceuticals derived from human plasma. The company’s portfolio includes 6 FDA-approved plasma-derived products, which are distributed in over 30 international markets.
WebsiteAlpha 1-Antitrypsin
Alpha 1-Antitrypsin Deficiency
KamRAB - HRIG
Rabies
Active rabies vaccine (US-FDA approved)
Rabies
Kamada AAT for inhalation
Emphysema
Kamada-API
Alpha 1-Antitrypsin Deficiency
Aerosolized, human, plasma-derived Alpha-1 Antitrypsin
Cystic Fibrosis
AAT(Alpha 1 Antitrypsin)
Type 1 Diabetes
Alpha-1 Antitrypsin (AAT, Glassia®)
Type 1 Diabetes Mellitus
Kamada Anti-SARS-CoV-2
Covid19
GLASSIA® and Institution standard of care (SOC)
Transplantation, Lung Rejection
Kamada-AAT for Inhalation
Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin
New Onset Type-1 Diabetes
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Alpha 1-Antitrypsin | Phase 3 | Alpha 1-Antitrypsin Deficiency | - | - |
KamRAB - HRIG | Phase 3 | Rabies | - | - |
Active rabies vaccine (US-FDA approved) | Phase 3 | Rabies | - | - |
Kamada AAT for inhalation | Phase 3 | Emphysema | - | - |
Kamada-API | Phase 3 | Alpha 1-Antitrypsin Deficiency | - | - |
Aerosolized, human, plasma-derived Alpha-1 Antitrypsin | Phase 2 | Cystic Fibrosis | - | - |
AAT(Alpha 1 Antitrypsin) | Phase 2 | Type 1 Diabetes | - | - |
Alpha-1 Antitrypsin (AAT, Glassia®) | Phase 2 | Type 1 Diabetes Mellitus | - | - |
Kamada Anti-SARS-CoV-2 | Phase 2 | Covid19 | - | - |
GLASSIA® and Institution standard of care (SOC) | Phase 2 | Transplantation, Lung Rejection | - | - |
Kamada-AAT for Inhalation | Phase 2 | Alpha-1 Antitrypsin Deficiency | - | - |
Alpha-1 Antitrypsin | Phase 2 | New Onset Type-1 Diabetes | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Kamada Ltd.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in Kamada Ltd.'s (KMDA) pipeline across Phase 3, Phase 2. Its lead program is Active rabies vaccine (US-FDA approved) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kamada Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Kamada Ltd. (KMDA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track KMDA biotech catalysts?→
Add KMDA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kamada Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
